Keywords：方药研究, 实验研究, 配方资产, 转化沟通, 3.5 裴氏软肝消痞丸对荷瘤小鼠肿瘤组织中Bcl-2表达的影响
Section Index
3.3 Effects of Pei's Soft Liver and Anti-Flatulence Pill on Immune Organs—Thymus and Spleen—in Tumor-Bearing Mice
In the model control group, the thymus and spleen of mice showed reduced volume and weight; some thymuses had unclear lobes and appeared grayish-white, while the spleens turned pale red. In the PRGXP low-, medium-, and high-dose groups as well as the cantharidin group, the thymic index (TI) was higher than that of the model control group. Specifically, in the PRGXP medium-dose group, the TI was (53.2±15.6) mg/10 g, a 31.4% increase compared with the model control group, which was statistically significant (P<0.05). Compared with the normal group, the TI of the model control group was significantly lower (P<0.05).
In the PRGXP low-, medium-, and high-dose groups and the cantharidin group, the splenic index (SI) was also higher than that of the model control group, with all differences being statistically significant (P<0.05); compared with the normal group, the SI of the model control group was markedly lower (P<0.05). See Table 2, Figures 3 and 4.
Table 2: Effects of Pei's Soft Liver and Anti-Flatulence Pill on Thymic Index and Splenic Index in Tumor-Bearing Mice (x±S)
| Group | Dose (g·kg⁻¹) | Number of Mice | TI (mg/10g) | TI Growth Rate (%) | SI (mg/10g) | SI Growth Rate (%) |
|---|---|---|---|---|---|---|
| Normal Group | — | 12 | 60.0±11.9 | — | 74.9±24.5 | — |
| Model Control Group | — | 12 | 40.5±6.3 | — | 44.8±12.6 | — |
| PRGXP low-dose group | 1.0 | 12 | 45.5±6.2 | 12.3 | 58.9±14.5 | 31.5 |
| PRGXP medium-dose group | 2.0 | 12 | 53.2±15.6* | 31.4 | 65.0±10.1* | 45.1 |
| PRGXP high-dose group | 4.0 | 12 | 47.7±23.3 | 17.8 | 55.2±15.9* | 23.2 |
| Cantharidin group | 0.25 | 12 | 52.9±17.3* | 30.6 | 63.6±15.8* | 42.0 |
Note: *P<0.05 compared with the model control group; △P<0.05 compared with the normal group
This chapter is prepared for online research and reading; for external materials, please align with original publications and the review process.